KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Ionis Pharmaceuticals (IONS) Receivables - Other (2016 - 2026)

Ionis Pharmaceuticals (IONS) has disclosed Receivables - Other for 18 consecutive years, with $73.7 million as the latest value for Q1 2026.

  • For Q1 2026, Receivables - Other rose 85.57% year-over-year to $73.7 million; the TTM value through Mar 2026 reached $73.7 million, up 85.57%, while the annual FY2025 figure was $66.1 million, 28.34% down from the prior year.
  • Receivables - Other hit $73.7 million in Q1 2026 for Ionis Pharmaceuticals, up from $66.1 million in the prior quarter.
  • Across five years, Receivables - Other topped out at $142.4 million in Q3 2023 and bottomed at $5.1 million in Q1 2024.
  • Average Receivables - Other over 5 years is $43.9 million, with a median of $27.3 million recorded in 2024.
  • Year-over-year, Receivables - Other skyrocketed 2042.35% in 2023 and then plummeted 87.41% in 2024.
  • Ionis Pharmaceuticals' Receivables - Other stood at $25.5 million in 2022, then surged by 282.87% to $97.8 million in 2023, then dropped by 5.72% to $92.2 million in 2024, then decreased by 28.34% to $66.1 million in 2025, then grew by 11.54% to $73.7 million in 2026.
  • According to Business Quant data, Receivables - Other over the past three periods came in at $73.7 million, $66.1 million, and $24.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.